Precision Medicine Software Developers Market by Target Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), Key Geographical Regions (North America, Europe, Asia-Pacific) and Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies): Industry Trends and Global Forecasts, 2021-2031

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    238

  • View Count
    1879

Example Insights

Precision-Medicine-Software-Developers-Market-Context Precision-Medicine-Software-Developers-Market-List-of-Precision-Medicine Precision-Medicine-Software-Developers-Market-Market-Landscape
Precision-Medicine-Software-Developers-Market-Competitiveness-Analysis Precision-Medicine-Software-Developers-Market-Patents-Analysis Precision-Medicine-Software-Developers-Market-Partnerships-and-Collaborations
Precision-Medicine-Software-Developers-Market-Funding-and-Investments Precision-Medicine-Software-Developers-Market-Opportunity  

Overview

Various studies have indicated that the genetic composition of two individuals is unlikely to be similar. This can be attributed to the fact that the genetic makeup of an individual is influenced by various factors, such as family history, as well as environmental and health conditions. Therefore, one treatment cannot be expected to be successful in every patient suffering from the same disorder. It is worth highlighting that the inability to report a health issue to a medical practitioner in its initial stage is expected to cost productivity losses worth over USD 40-90 billion, each year. Further, frequent hospitals visits can cause additional financial burden on patients. In order to mitigate the aforementioned challenges, healthcare professionals are shifting towards the use of personalized / precision medicine. This approach, as opposed to the one-size-fits-all approach, enables healthcare professionals to offer a precise treatment option for a specific disease that is likely to prove effective for a group of individuals. This domain has the ability to reduce treatment burden across many therapeutic areas including oncological disorders, rheumatology disorders.

Given the various advantages offered by precision medicine, healthcare organizations are gradually becoming more interested in adopting such solutions. Further, with the advent of bioinformatics and artificial intelligence tools, there has been a significant rise in the adoption of such applications. For instance, in June 2020, Infosys launched its proprietary personalized medicine solution, equipped with latest SAP S/4HANA® technology, to gain intelligent insights to deliver personalized experience to patients. It is worth highlighting that precision medicine software solutions are widely used by healthcare providers for the diagnosis, as well as prognosis, of the disease. However, the scope is being continuously expanded in order to include the prevention and recovery of life threatening diseases. At present, several software applications integrate clinical and diagnostic data, along with financial data, offering deeper and precise insights to healthcare providers, as well as helping them improve patient outcomes. Players engaged in the development of precision medicine software applications have observed a significant growth over the past few years. More than 120 software solutions have been developed and are available commercially. It is also worth highlighting that over USD 2 billion has been invested in this domain by various stakeholders in the last four years. As a result of the rising adoption and preference for precision medicine software applications, coupled to the ongoing efforts of software providers to further improve the current software solutions, we believe that the precision medicine software services market is likely to witness significant growth in the foreseen future.

Scope of the Report

The “Precision Medicine Software Developers Market by Target Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), Key Geographical Regions (North America, Europe, Asia-Pacific) and Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies): Industry Trends and Global Forecasts, 2022-2032”  report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of precision medicine software in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features the following:

  • A detailed overview of the current market landscape of precision medicine software developers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of platforms (cloud-based and on-premises), purpose of software (diagnosis, analysis, treatment), type of data (genomic data, clinical data, image data and others), therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders) and types of end users (healthcare providers, research and government institutes, pharmaceutical and biotech companies). 
  • Elaborate profiles of key players engaged in the development of precision medicine software applications. Each profile features a brief overview of the company, along with its information on technology / service portfolio, recent developments and an informed future outlook.
  • A detailed analysis of the various patents that have been filed / granted within this domain, since 2018. It highlights the key trends associated with these patents across several relevant parameters, such as publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of organization, leading patent assignees and most active players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and patent valuation.
  • An analysis of the recent partnerships inked between various players engaged in this domain, during the period 2018-2021, based on several relevant parameters, such as year of partnership, type of partnership model adopted, regional distribution (continent and country-wise) and most active players (in terms of number of partnerships inked).
  • A detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO)) undertaken by companies engaged in this domain, during the period 2018-2021.
  • A detailed analysis based on a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis.

One of the key objectives of the report was to estimate the existing market size and future potential of precision medicine software developers, over the coming decade. Further, we have provided an informed estimate of the market’s evolution, during the period 2021-2031, based on several relevant parameters, such as adoption trends, and expected price variations for these products. The report features the likely distribution of the current and forecasted opportunity within the precision medicine software market across [A] Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), [B] Key Geographical Regions (North America, Europe, Asia-Pacific), [C] Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies).

All actual figures have been sourced and analyzed from publicly available information forums and secondary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in the development of precision medicine software applications?
  • Which type of platform is more likely to outreach the market in the near future?
  • Which companies are actively engaged in the development of precision medicine software applications? 
  • What are the major therapeutic areas targeted by various precision medicine software applications?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in this domain? 
  • Who are the target users of precision medicine software applications?
  • What are the different types of data being handled by precision medicine software developers?
  • What is the main purpose for using precision medicine software applications? 
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of precision medicine software market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to precision medicine and precision medicine software solutions and its historical evolution. It further includes a brief outline on the need for software solutions, along with information on the various patient monitoring related services offered by players engaged in this domain. Furthermore, it highlights prevalent advantages and key challenges associated with precision medicine software, featuring details related to the current and future trends in the domain.

Chapter 4 provides a detailed overview of the overall market landscape of players engaged in providing precision medicine software solutions, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of platforms (cloud-based, on-premises),  purpose of software (diagnosis, analysis, treatment), type of data handled (genomic data, clinical data, image data, omics data), therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders), types of end users (healthcare providers, research and government institutes, pharmaceutical and biotech companies). 

Chapter 5 includes detailed profiles of the key players that are active in this domain. Each profile includes a brief overview of the company, its information on technology / service portfolio, recent developments and an informed future outlook.

Chapter 6 features a comprehensive company competitiveness analysis, highlighting prominent players among two peer groups (North America and Europe and Asia Pacific) that we came across during our research. The chapter provides a comparative analysis of the companies within each peer group on the basis of supplier strength (considering a company’s overall experience in the industry).

Chapter 7 provides an overview of the various patents related to precision medicine software solutions that have been filed / granted, since 2018. It highlights the key trends associated with these patents across various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of organization, leading patent assignees and the leading players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 8 features an analysis of the recent partnerships inked between precision medicine software developers, during the period 2018-2021 Additionally, it includes a brief description of the various types of partnerships models (such as product / software integration agreement, service alliance, service agreement, product / software development agreement, full business acquisition, product / software distribution agreement, product / software utilization agreement, and product portfolio acquisition) that have been adopted by stakeholders engaged in this domain, during the period 2018-2021.

Chapter 9 provides an analysis of various investments made by players engaged in this domain based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (such as, venture capital, private equity, secondary offerings, debt, initial public offering (IPO), other equity, seed, grant, and others), along with information on the most active players (in terms of number of funding instances and amount raised) and most active investors (in terms of number of funding instances). 

Chapter 10 features a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

Chapter 11 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders), [B] key geographical regions (North America, Europe, Asia-Pacific) and [C] end user (healthcare providers, research & government institutes, pharmaceutical & biotech companies). 

Chapter 12 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall precision medicine software developers.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Precision Medicine
3.2.1. Evolution of Precision Medicine
3.2.2. Novel Approaches in Precision Medicine
3.2.2.1. Biomarkers and Decision Making
3.2.2.2. Genomics, Epigenetics and MicroRNAs as Emerging Biomarkers
3.2.2.3 Biomarker Multiplexing
3.2.2.4. Digital Biomarkers
3.2.2.5. Metabolomics

3.3. Key Technology Platforms
3.3.1. Cloud Based
3.3.2. On-Premises

3.4. Key Challenges Faced by Precision Medicine Software Developers
3.4.1. Unprecedented Data Volumes
3.4.2. Interpreting Data Deluge at the Level of Individual
3.4.3. Incorporation into the Clinic

3.5. Application Areas
3.6. Benefits of Precision Medicine over Traditional Treatment Modalities
3.6.1. Benefits to Patients
3.6.2. Benefits to Healthcare Providers

3.7. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Precision Medicine Software Developers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region
4.2.4. Analysis by Status of Development
4.2.5. Analysis by Type of Platform
4.2.6. Analysis by Regulatory Accreditations
4.2.5. Analysis by Purpose of Software
4.2.6. Analysis by Type of Data Handled
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Type of End-User

4.3. Most Active Players: Analysis by Number of Software

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Precision Medicine Software Developers
5.2.1. AceTech
5.2.1.1. Company overview
5.2.1.2. Product portfolio
5.2.1.3. Recent Developments and Future Outlook

5.2.2. Ariel Precision Medicine 
5.2.2.1. Company Overview
5.2.2.2. Product Portfolio
5.2.2.3. Recent Developments and Future Outlook

5.2.3. C2i Genomics 
5.2.3.1. Company Overview
5.2.3.2. Product Portfolio
5.2.3.3. Recent Developments and Future Outlook

5.2.4. Genedata 
5.2.4.1. Company Overview
5.2.4.2. Product Portfolio
5.2.4.3. Recent Developments and Future Outlook

5.2.5. Inspirata 
5.2.5.1. Company Overview
5.2.5.2. Product Portfolio
5.2.5.3. Recent Developments and Future Outlook

5.2.6. IQVIA 
5.2.6.1. Company Overview
5.2.6.2. Product Portfolio
5.2.6.3. Recent Developments and Future Outlook

5.3. Additional Profiles
5.3.1. Fabric Genomics 
5.3.1.1. Company Overview
5.3.1.2. Product Portfolio
5.3.1.3. Recent Developments and Future Outlook

5.3.2. GenomOncology 
5.3.2.1. Company Overview
5.3.2.2. Product Portfolio
5.3.2.3. Recent Developments and Future Outlook

5.3.3. Human Longevity 
5.3.3.1. Company Overview
5.3.3.2. Product Portfolio
5.3.3.3. Recent Developments and Future Outlook

5.3.4. SOPHiA GENETICS
5.3.4.1. Company Overview
5.3.4.2. Product Portfolio
5.3.4.3. Recent Developments and Future Outlook

5.3.5. Syapse
5.3.5.1. Company Overview
5.3.5.2. Product Portfolio
5.3.5.3. Recent Developments and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Company Competitiveness Analysis Based on Company size
6.2.1. Assumptions / Key Parameters
6.2.2. Methodology
6.2.3. Company Competitiveness Analysis: Small Companies
6.2.4. Company Competitiveness Analysis: Mid-sized Companies
6.2.5. Company Competitiveness Analysis: Large and Very Large Companies

6.3. Company Competitiveness Analysis Based on Geographical Region
6.3.1. Assumptions / Key Parameters
6.3.2. Methodology
6.3.3. Company Competitiveness Analysis: Companies in North America
6.3.4. Company Competitiveness Analysis: Companies in Europe, Asia-Pacific and Rest of the World

6.4. Key Players Based on Proprietary Scores

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Precision Medicine Software Developers: Patent Analysis
7.3.1. Analysis by Type of Patent
7.3.2. Analysis by Publication Year 
7.3.3. Analysis by Publication Year and Type of Patent
7.3.4. Analysis by Geography
7.3.4.1. Patent Analysis: North America Scenario
7.3.4.2. Patent Analysis: Europe Scenario
7.3.4.3. Patent Analysis: Asia-Pacific Scenario

7.3.5.  Analysis by CPC Symbols
7.3.6. Analysis by Emerging Focus Area
7.3.7. Most Active Players: Analysis by Number of Patents
7.3.8. Most Active Inventors: Analysis by Number of Patents
7.3.9. Analysis by Type of Organization
7.3.10. Patent Benchmarking Analysis
7.3.10.1. Analysis by Patent Characteristics
7.3.10.1.1. Tempus Labs and GenomSys
7.3.10.1.2. Other Leading Patent Assignees

7.3.11. Patent Valuation Analysis
7.3.12. Legal Status Analysis
7.3.12.1. Analysis by Legal Status
7.3.12.2. Analysis by Geography and Legal Status

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Precision Medicine Software Developers: List of Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Year of Partnership and Focus Area
8.3.6. Analysis by Type of Partnership and Focus Area
8.3.7. Analysis by Therapeutic Area
8.3.8. Analysis by Type of Partnership and Type of Platform
8.3.9. Analysis by Type of Partnership and Type of Data Handled

8.3.10. Analysis by Region
8.3.10.1. Continent-wise Distribution
8.3.10.2. Intercontinental and Intracontinental Distribution
8.3.10.3. Country-wise Distribution

8.3.11. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Precision Medicine Software Developers: Funding and Investment Analysis
9.3.1 Analysis by Number of Funding Instances by Year
9.3.2. Analysis of Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Regional Analysis by Amount Invested
9.3.5. Analysis by Year and Type of Funding
9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
9.3.7. Key Investors: Analysis by Number of Instances
9.3.8. Analysis by Purpose of Investment
9.3.9. Analysis by Type of Data Handled
9.3.10. Analysis by Therapeutic Area

10. ATTRACTIVENESS COMPETETIVENESS MATRIX
10.1. Chapter Overview
10.2. AC Matrix: Overview
10.2.1. Strong Business Segments
10.2.2. Average Business Segments
10.2.3. Weak Business Segments

10.3. AC Matrix: Analytical Methodology
10.4. AC Matrix: Precision Medicine Software Developers for Different Therapeutic Areas
10.5. AC Matrix: Precision Medicine Software Developers in Different Regions

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Assumptions
11.3. Global Precision Medicine Software Developers Market, 2021-2032
11.3.1. Precision Medicine Software Developers Market, 2021-2032: Analysis by Therapeutic Area
11.3.1.1. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032
11.3.1.2. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032
11.3.1.3. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032
11.3.1.4. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032
11.3.1.5. Precision Medicine Software Developers Market for Other Disorders, 2021-2032

11.3.2. Precision Medicine Software Developers Market, 2021-2032: Analysis by Type of End-User
11.3.2.1. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032
11.3.2.2. Precision Medicine Software Developers Market for Hospitals, 2021-2032

11.3.3. Precision Medicine Software Developers Market, 2021-2032: Analysis by Region
11.3.3.1. Precision Medicine Software Developers Market in North America, 2021-2032
11.3.3.2. Precision Medicine Software Developers Market in Europe, 2021-2032
11.3.3.3. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World, 2021-2032

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
12.7. Concluding Remarks

13. CONCLUDING REMARKS
13.1. Chapter Overview

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES

List Of Figures

Figure 2.1. Executive Summary: Developer Landscape
Figure 2.2. Executive Summary: Partnerships and Collaborations
Figure 2.3. Executive Summary: Funding and Investments
Figure 2.4. Executive Summary: Patent Analysis
Figure 2.5. Executive Summary: Market Forecast
Figure 3.1. Evolution of Precision Medicine
Figure 3.2. Applications of Precision Medicine
Figure 4.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Figure 4.2. Precision Medicine Software Developers: Distribution by Company Size
Figure 4.3. Precision Medicine Software Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4. Precision Medicine Software Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Figure 4.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 4.7. Precision Medicine Software Applications: Distribution by Status of Development
Figure 4.8. Precision Medicine Software Applications: Distribution by Status of Development and Region
Figure 4.9. Precision Medicine Software Applications: Distribution by Type of Platform
Figure 4.10. Precision Medicine Software Applications: Distribution by Regulatory Accreditation Received
Figure 4.11. Precision Medicine Software Applications: Distribution by Purpose of Software Applications
Figure 4.12. Precision Medicine Software Applications: Distribution by Type of Data Handled
Figure 4.13. Precision Medicine Software Applications: Distribution by Status of Development and Type of Data Handled
Figure 4.14. Precision Medicine Software Applications: Distribution by Therapeutic Area
Figure 4.15. Precision Medicine Software Applications: Distribution by Therapeutic Area and Status of Development
Figure 4.16. Precision Medicine Software Applications: Distribution by Type of Data Handled and Therapeutic Area
Figure 4.17. Precision Medicine Software Applications: Distribution by Type of End-User
Figure 4.18. Most Active Players: Distribution by Number of Software Applications
Figure 6.1. Company Competitiveness Analysis: Small Companies Scenario
Figure 6.2. Company Competitiveness Analysis: Mid-sized Companies Scenario
Figure 6.3. Company Competitiveness Analysis: Large and Very Large Companies Scenario
Figure 6.4. Company Competitiveness Analysis: Companies in North America
Figure 6.5. Company Competitiveness Analysis: Companies in Europe, Asia-Pacific and Rest of the World
Figure 6.6. Key Players Based on Proprietary Scores
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Distribution by Publication Year, 2018-2021
Figure 7.3. Patent Analysis: Distribution of Granted Patents by Publication Year
Figure 7.4. Patent Analysis: Distribution by Geography (Continent-wise)
Figure 7.5. Patent Analysis: North America Scenario (Region-wise)
Figure 7.6. Patent Analysis: Europe Scenario (Region-wise)
Figure 7.7. Patent Analysis: Asia-Pacific Scenario (Region-wise)
Figure 7.8. Patent Analysis: Distribution by CPC Classification
Figure 7.9. Patent Analysis: Distribution by Emerging Focus Area
Figure 7.10. Most Active Players: Distribution by Number of Patents
Figure 7.11. Most Active Inventors: Distribution by Number of Patents
Figure 7.12. Overall Intellectual Property Portfolio: Distribution by Type of Organization
Figure 7.13. Patent Benchmarking Analysis: Tempus Labs and GenomSys
Figure 7.14. Patent Benchmarking Analysis: Other Leading Players
Figure 7.15. Patent Analysis: Distribution by Patent Age
Figure 7.16. Patent Analysis: Patent Relative Valuation
Figure 7.17. Patent Analysis: Distribution by Legal Status
Figure 7.18. Patent Analysis: Distribution by Legal Status and Geography
Figure 8.1. Partnerships: Distribution by Year of Partnership
Figure 8.2. Partnerships: Distribution by Type of Partnership
Figure 8.3. Partnerships: Distribution by Year and Type of Partnership
Figure 8.4. Partnerships: Distribution by Focus Area
Figure 8.5. Heat Map: Distribution by Year of Partnership and Focus Area
Figure 8.6. Partnerships: Distribution by Type of Partnership and Focus Area
Figure 8.7. Partnerships: Distribution by Therapeutic Area
Figure 8.8. Partnerships: Distribution by Type of Partnership and Type of Platform
Figure 8.9. Partnerships: Distribution by Type of Partnership and Type of Data Handled
Figure 8.10. Partnerships: Continent-wise Distribution
Figure 8.11. Partnerships: Intercontinental and Intracontinental Agreements
Figure 8.12. Partnerships: Country-wise Distribution
Figure 8.13. Most Active Players: Distribution by Number of Partnerships
Figure 9.1. Funding and Investment Analysis: Distribution by Year of Funding (2018-2021)
Figure 9.2. Funding and Investment Analysis: Distribution of Amount Invested by Year (USD Million)
Figure 9.3. Funding and Investment Analysis: Distribution Type of Funding, 2018-2021
Figure 9.4. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2018-2021 (USD Million)
Figure 9.5. Funding and Investment Analysis: Summary of Investments, 2018-2020 (USD Million)
Figure 9.6. Funding and Investment Analysis: Distribution by Geography
Figure 9.7. Funding and Investment Analysis: Distribution of Instances by Geography 2018-2020
Figure 9.8. Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2018-2021
Figure 9.9. Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, 2018-2021 (USD Million)
Figure 9.10. Most Active Players: Distribution by Number of Funding Instances
Figure 9.11. Most Active Investors: Distribution by Amount Raise (USD Million)
Figure 9.12. Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.13. Funding and Investment Analysis: Distribution by Purpose of Investment
Figure 9.14. Funding and Investment Analysis: Distribution by Type of Data Handled
Figure 9.15. Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 10.1. AC Matrix: Pictorial Representation
Figure 10.2. AC Matrix: Precision Medicine Software Developers for Various Therapeutic Areas
Figure 10.3. AC Matrix: Precision Medicine Software Developers in Regions
Figure 11.1. Global Precision Medicine Software Developers Market, 2021-2032 (USD Million)
Figure 11.2. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2022 and 2032
Figure 11.3. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032 (USD Million)
Figure 11.4. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032 (USD Million)
Figure 11.5. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032 (USD Million)
Figure 11.6. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032 (USD Million)
Figure 11.7. Precision Medicine Software Developers Market for Other Disorders, 2021-2032 (USD Million)
Figure 11.8. Precision Medicine Software Developers Market: Distribution by Types of End-users, 2022 and 2032 (USD Million)
Figure 11.9. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032 (USD Million)
Figure 11.10. Precision Medicine Software Developers Market for Hospitals, 2021-2032 (USD Million)
Figure 11.11. Precision Medicine Software Developers Market: Distribution by Geography, 2022 and 2032 (USD Million)
Figure 11.12. Precision Medicine Software Developers Market in North America, 2021-2032 (USD Million)
Figure 11.13. Precision Medicine Software Developers Market in Europe, 2021-2032 (USD Million)
Figure 11.14. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World, 2021-2032 (USD Million)
Figure 12.1. Precision Medicine Software Developers: SWOT Analysis
Figure 12.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1. Concluding Remarks: Current Market Landscape
Figure 13.2. Concluding Remarks: Patent Analysis
Figure 13.3. Concluding Remarks: Partnerships and Collaborations
Figure 13.4. Concluding Remarks: Funding and Investment Analysis
Figure 13.5. Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1. Precision Medicine Software Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 4.2. Precision Medicine Software Applications: Information on Software Applications, Status of Development, and Compliance
Table 4.3. Precision Medicine Software Applications: Information on Therapeutic Area, Type of Data Handled, Purpose of Software and Type of End-User
Table 5.1. AceTech: Company Overview
Table 5.2. AceTech: Product Portfolio
Table 5.3. Ariel Precision Medicine: Company Overview
Table 5.4. Ariel Precision Medicine: Product Portfolio
Table 5.5. Ariel Precision Medicine: Recent Developments and Future Outlook
Table 5.6. C2i Genomics: Company Overview
Table 5.7. C2i Genomics: Product Portfolio
Table 5.8. C2i Genomics: Recent Developments and Future Outlook
Table 5.9. Genedata: Company Overview
Table 5.10. Genedata: Product Portfolio
Table 5.11. Genedata: Recent Developments and Future Outlook
Table 5.12. Inspirata: Company Overview
Table 5.13. Inspirata: Product Portfolio
Table 5.14. IQVIA: Company Overview
Table 5.15. IQVIA: Product Portfolio
Table 5.16. IQVIA: Recent Developments and Future Outlook
Table 5.17. Fabric Genomics: Company Overview
Table 5.18. Fabric Genomics: Product Portfolio
Table 5.19. GenomOncology: Company Overview
Table 5.20. GenomOncology: Product Portfolio
Table 5.21. Human Longevity: Company Overview
Table 5.22. Human Longevity: Product Portfolio
Table 5.23. SOPHiA GENETICS: Company Overview
Table 5.24. SOPHiA GENETICS: Product Portfolio
Table 5.25. SOPHiA GENETICS: Recent Developments and Future Outlook
Table 5.26. Syapse: Company Overview
Table 5.27. Syapse: Product Portfolio
Table 5.28. Syapse: Recent Developments and Future Outlook
Table 7.1. Patent Analysis: List of Top CPC Symbols
Table 7.2. Patent Analysis: Summary of Benchmarking Analysis
Table 7.3. Patent Analysis: Various Categorization based on Weighted Scores
Table 7.4. Patent Analysis: List of Leading Patents (in terms of highest relative valuation)
Table 8.1. Partnerships and Collaborations: List of Partnerships
Table 8.2. Partnerships and Collaborations: Information on Focus Area, Therapeutic Area, Type of Platform and Type of Data Handled
Table 9.1. Precision Medicine Software Developers Market: Funding and Investments, 2018-2021
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 9.3 Funding and Investment Analysis: Summary of Venture Capital Round
Table 9.4 Fundings and Investments: Information on Purpose of Investment, Type of Data Handled and Therapeutic Area
Table 14.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Table 14.2. Precision Medicine Software Developers: Distribution by Company Size
Table 14.3. Precision Medicine Software Developers: Distribution by Location of Headquarters (Region-wise)
Table 14.4. Precision Medicine Software Developers: Distribution by Location of Headquarters (Country-wise)
Table 14.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Table 14.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 14.7. Precision Medicine Software Applications: Distribution by Status of Development
Table 14.8. Precision Medicine Software Applications: Distribution by Status of Development and Region
Table 14.9. Precision Medicine Software Applications: Distribution by Type of Platform
Table 14.10. Precision Medicine Software Applications: Distribution by Regulatory Accreditations Received
Table 14.11. Precision Medicine Software Applications: Distribution by Type of Data Handled
Table 14.12. Precision Medicine Software Applications: Distribution by Status of Development and Type of Data Handled
Table 14.13. Precision Medicine Software Applications: Distribution by Therapeutic Area
Table 14.14. Precision Medicine Software Applications: Distribution by Therapeutic Area and Status of Development
Table 14.15. Precision Medicine Software Applications: Distribution by Type of Data Handled and Therapeutic Area
Table 14.16. Precision Medicine Software Developers: Distribution by Type of End-User
Table 14.17. Most Active Players: Distribution by Number of Software Applications
Table 14.18. Patent Analysis: Distribution by Type of Patent
Table 14.19. Patent Analysis: Distribution by Publication Year, 2018-2021
Table 14.20. Patent Analysis: Distribution of Granted Patents by Publication Year
Table 14.21. Patent Analysis: Distribution by Geography (Continent-wise)
Table 14.22. Patent Analysis: North America Scenario (Region-wise)
Table 14.23. Patent Analysis: Europe Scenario (Region-wise)
Table 14.24. Patent Analysis: Asia-Pacific Scenario (Region-wise)
Table 14.25. Most Active Players: Distribution by Number of Patents
Table 14.26. Most Active Inventors: Distribution by Number of Patents
Table 14.27. Overall Intellectual Property Portfolio: Distribution by Type of Organization
Table 14.28. Patent Analysis: Distribution by Patent Age
Table 14.29. Patent Analysis: Patent Relative Valuation
Table 14.30. Patent Analysis: Distribution by Legal Status
Table 14.31. Patent Analysis: Distribution by Legal Status and Geography
Table 14.32. Partnerships: Distribution by Year of Partnership
Table 14.33. Partnerships: Distribution by Type of Partnership
Table 14.34. Partnerships: Distribution by Year and Type of Partnership
Table 14.35. Partnerships: Distribution by Focus Area
Table 14.36. Partnerships: Distribution by Year of Partnership and Focus Area
Table 14.37. Partnerships: Distribution by Type of Partnership and Focus Area
Table 14.38. Partnerships: Distribution by Therapeutic Area
Table 14.39. Partnerships: Country-wise Distribution
Table 14.40. Most Active Players: Distribution by Number of Partnerships
Table 14.41. Funding and Investment Analysis: Distribution by Year of Funding (2018-2021)
Table 14.42. Funding and Investment Analysis: Distribution of Amount Invested by Year (USD Million)
Table 14.43. Funding and Investment Analysis: Distribution of Type of Funding, 2018-2021
Table 14.44. Funding and Investment Analysis: Distribution of Amount Invested by the Type of Funding, 2018-2021 (USD Million)
Table 14.45. Funding and Investment Analysis: Summary of Investments, 2018-2020 (USD Million)
Table 14.46. Funding and Investment Analysis: Distribution by Geography
Table 14.47. Funding and Investment Analysis: Distribution of Instances by Geography 2018-2020
Table 14.48. Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2018-2021
Table 14.49. Funding and Investment Analysis: Distribution of Instances by Year, Type of Funding and Amount Invested, 2018-2021 (USD Million)
Table 14.50. Most Active Players: Distribution by Number of Funding Instances
Table 14.51. Most Active Investors: Distribution by Amount Raise (USD Million)
Table 14.52. Funding and Investment Analysis: Distribution by Type of Investor
Table 14.53. Funding and Investment Analysis: Distribution by Purpose of Investment
Table 14.54. Funding and Investment Analysis: Distribution by Type of Data Handled
Table 14.55. Funding and Investment Analysis: Distribution by Therapeutic Area
Table 14.56. Global Precision Medicine Software Developers Market, 2021-2032 (USD Million)
Table 14.57. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2022 and 2032
Table 14.58. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032 (USD Million)
Table 14.59. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032 (USD Million)
Table 14.60. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032 (USD Million)
Table 14.61. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032 (USD Million)
Table 14.62. Precision Medicine Software Developers Market for Other Disorders, 2021-2032 (USD Million)
Table 14.63. Precision Medicine Software Developers Market: Distribution by Types of End-users, 2022 and 2032 (USD Million)
Table 14.64. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032 (USD Million)
Table 14.65. Precision Medicine Software Developers Market for Hospitals, 2021-2032 (USD Million)
Table 14.66. Precision Medicine Software Developers Market: Distribution by Geography, 2022 and 2032 (USD Million)
Table 14.67. Precision Medicine Software Developers Market in North America, 2021-2032 (USD Million)
Table 14.68. Precision Medicine Software Developers Market in Europe, 2021-2032 (USD Million)
Table 14.69. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World , 2021-2032 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 2bPrecise
  2. 2nd.MD
  3. 4D Path
  4. 83North
  5. AB Enzymes
  6. Abu Dhabi Health Data Services
  7. ACE & Company
  8. AceTech
  9. Admera Health
  10. Advaita
  11. AdventHealth
  12. Adventist Health
  13. Aetna
  14. AG Mednet
  15. Agilent Technologies
  16. Ainnova Tech
  17. AIQ Solutions
  18. Alexandria Venture Investments
  19. AliveAndKickn
  20. Allscripts
  21. Ally Bridge Group
  22. Altis Labs
  23. Altium Capital
  24. Alychlo
  25. AMedSU
  26. American Heart Association
  27. American Society of Clinical Oncology
  28. Amgen
  29. AMITA Health
  30. aMoon
  31. AMRA Medical
  32. PathWest Laboratory Medicine
  33. ARCH Venture Partners
  34. Ariel Precision Medicine
  35. ARUP Laboratories
  36. Ascension Ventures
  37. Asset Management Ventures
  38. Astarte Medical
  39. AstraZeneca
  40. ATW Partners
  41. Audacy
  42. Australian BioCommons
  43. Australian Research Data Commons (ARDC)
  44. Axiom Associates
  45. Babylon Health
  46. Baillie Gifford
  47. Bain Capital Ventures
  48. Bainbridge Health
  49. Balderton Capital
  50. Barts Health NHS Trust
  51. Bayer
  52. BC Platforms
  53. Beacon Capital
  54. Belgian Society of Medical Oncology 
  55. BenevolentAI
  56. Biocept 
  57. BioVariance
  58. Blueprint Medicines
  59. Boehringer Ingelheim Venture Fund
  60. Brainomix
  61. Breakthrough Genomics
  62. Briban Invest
  63. Bristol Myers Squibb
  64. Broad Institute
  65. Business Development Bank of Canada
  66. C2i Genomics
  67. Caesar
  68. Apple
  69. Cancer Genetics
  70. CancerIQ
  71. Capital Midwest Fund
  72. Caris Life Sciences
  73. Casdin Capital
  74. Catipult.AI
  75. Clayton, Dubilier & Rice (CD&R)
  76. Celgene
  77. Centana Growth Partners
  78. CENTOGENE
  79. Centro Hospitalar Lisboa Ocidental 
  80. Cergentis
  81. Children’s Brain Tumor Tissue Consortium
  82. Chimera Partners
  83. Cigna Ventures
  84. Circle Cardiovascular Imaging
  85. Claremont Creek Ventures
  86. Cofactor Genomics
  87. Cohesic
  88. Colle Capital
  89. Color
  90. Community Health Network
  91. ConCR
  92. Connect Ventures
  93. Cornerstone Specialty Network  
  94. Cortex
  95. Crohn’s & Colitis Foundation
  96. CureMatch
  97. Curii
  98. Data4Cure
  99. Datavant
  100. Decentralized Trials & Research Alliance
  101. Dell Technologies
  102. Diagnomics
  103. Diagnostic Laboratory Services
  104. Dian Diagnostics
  105. Discovery Life Sciences
  106. DNA Compass
  107. DNAnexus
  108. Dolby Family Ventures
  109. DoseMe (Acquired by Tabula Rasa HealthCare)
  110. DrChrono
  111. Driehaus Capital Management
  112. Duquesne Family Office
  113. Echo Health Ventures
  114. Eiffel Investment
  115. Elekta
  116. Elysia Capital
  117. Emory Healthcare
  118. Endeavour Vision
  119. e-NIOS 
  120. EnvoyAI
  121. Epic App Orchard
  122. EpigeneticsRx
  123. Esplanade Ventures
  124. Essen University
  125. Eurazeo
  126. European Organisation for Research and Treatment of Cancer (EORTC)
  127. European Specialist Investment
  128. EW Healthcare Partners
  129. Fabric Genomics
  130. Famille C Invest
  131. Farsight Genome Systems
  132. Feist-Weiller Cancer Center
  133. First Round Capital
  134. Flatiron Health
  135. Fluidigm
  136. Flywheel
  137. Foresite Capital
  138. Foundation Medicine
  139. F-Prime Capital
  140. Franklin Templeton
  141. Friends of Cancer Research
  142. GE Healthcare
  143. Geisinger
  144. Genedata
  145. General Catalyst
  146. Generation Investment Management
  147. Genetic Alliance
  148. Genetic Technologies
  149. GeneXplain
  150. Genmab
  151. Genome Medical
  152. GenomOncology
  153. Genomelink
  154. Genomenon
  155. Genomics England
  156. Genomind
  157. GenomOncology
  158. GenomSys
  159. Genospace
  160. GenXys Health Care Systems
  161. Gilead Sciences
  162. GNS Healthcare
  163. Golden Helix
  164. Green Shield Canada
  165. GreenM
  166. GV
  167. Hamilton Health Sciences
  168. Healix
  169. Health Catalyst Capital
  170. Health Innovation Manchester
  171. Healthgen AI
  172. HealthQuad
  173. Hearst Health
  174. Heritas Capital
  175. Highmark Health
  176. Hitachi
  177. Hôpital Foch
  178. Houston Methodist
  179. Huami
  180. HudsonAlpha Institute
  181. Human Longevity
  182. Hygea Precision Medicine 
  183. Hyperfine
  184. Ibex Medical Analytics
  185. IBM
  186. International Development Association (IDA)
  187. Idinvest Partners
  188. iGlobe Partners
  189. Illumina
  190. Illumina Ventures
  191. Imaging Biometrics
  192. Imaginostics
  193. ImmunityBio
  194. Indiana Clinical and Translational Sciences Institute
  195. Indiana University
  196. Industrifonden
  197. iNDX.Ai
  198. InformedDNA
  199. Innovatus Capital Partners
  200. Inova Health System
  201. InsightRX
  202. Inspirata
  203. Integrated DNA Technologies
  204. Intellihealth
  205. Interactive Biosoftware
  206. Intermountain Healthcare
  207. Intero Life Sciences
  208. Intertrust Technologies
  209. IntrinsiQ Specialty Solutions
  210. IQVIA
  211. IRA Capital
  212. Janssen
  213. JDRF
  214. JiNan Danjier
  215. Kamet Ventures
  216. Kinship
  217. Koninklijke Philips
  218. Konyang University Hospital
  219. Kura Oncology
  220. LabCorp
  221. Lifebit
  222. LifeOmic Health
  223. Livongo
  224. LSS
  225. LunaPBC
  226. M2Gen
  227. MacroGenics
  228. Marienhaus Hospital
  229. Mary Crowley Cancer Research
  230. Mayo Clinic
  231. McKesson Ventures
  232. medASTUTE
  233. Medfusion
  234. Medical University of South Carolina
  235. Medidata
  236. MedImpact
  237. Medimsight
  238. Medipredict
  239. Medley Genomics
  240. Merck
  241. Merck Global Health Innovation Fund
  242. Merstal
  243. Merus
  244. Metabolon
  245. Microsoft
  246. MidCap Financial
  247. MindX Sciences
  248. Mission Bio
  249. Moffitt Cancer Center
  250. Molecular Health
  251. MolecularMatch
  252. MTIP
  253. Multiple Myeloma Research Foundation
  254. Murfreesboro Medical Clinic & SurgiCenter
  255. mymo.AI
  256. Myriad Genetics
  257. NantHealth
  258. NantOmics 
  259. Nashville Veterans Affairs Hospital
  260. Natera
  261. National Cancer Center
  262. National Cancer Institute
  263. National Institute of Health
  264. NeoGenomics 
  265. New Enterprise Associates
  266. Nextrans
  267. NFX
  268. NHS
  269. National Instruments (NI)
  270. National Institutes of Health (NIH)
  271. Nimbus Synergies
  272. Northpond Ventures
  273. NorthShore University HealthSystem
  274. Northwell Health
  275. Northwest Firefighters Benefits Trust
  276. Notable
  277. Novartis
  278. Novo Holdings
  279. NovogeneAIT Genomics
  280. NYU Grossman School of Medicine
  281. Octopus Ventures
  282. Ohio State University
  283. Olea Medical
  284. Oncora Medical
  285. OncXerna Therapeutics
  286. OneOncology
  287. Oracle
  288. Orion Health
  289. Osage University Partners
  290. Outcomes4Me
  291. Oxford University
  292. Pancreatic Cancer Action Network
  293. Paragon Genomics
  294. Parexel
  295. Parkwalk Advisors
  296. Pentech Ventures
  297. Perceiv AI
  298. Perceptive Advisors
  299. Personal Genome Diagnostics
  300. Pfizer
  301. Pharmatics
  302. PhenoTips®
  303. Phillips
  304. Phosphorus 
  305. PierianDx
  306. Pillar Biosciences
  307. Pinnacle
  308. PipelineRx
  309. Planven Entrepreneur Ventures
  310. Precision Digital Health
  311. Precision for Medicine
  312. Precision Health Informatics 
  313. Precision Health Software
  314. Premier
  315. Preon Capital
  316. Prisma Health
  317. Proscia
  318. Prudential Financial
  319. Psyche Systems
  320. Psychiatry-UK
  321. Pygar
  322. Q² Solutions
  323. QIAGEN
  324. Qlucore
  325. QMENTA
  326. QNA Dx
  327. Quadria Capital
  328. Quantgene
  329. QUBIS
  330. Quest Diagnostics
  331. Qynapse
  332. Renalytix AI
  333. Renown Health
  334. RetInSight
  335. Revelation Alpine
  336. Revolution Growth
  337. Roche
  338. Rock River Capital Partners
  339. 30Ventures
  340. RTI International
  341. Russell Microcap Index
  342. RxGenomix
  343. RXVIP Concierge
  344. Safeguard Scientifics
  345. San Francisco Otolaryngology
  346. Sanford Health
  347. Sano Genetics
  348. Sanofi
  349. SAP
  350. SCA Robotics
  351. ScienceVision
  352. ScreenPoint Medical
  353. Section 32
  354. Sentieon
  355. Seoul National University Hospital
  356. Sequoia
  357. Seven Bridges
  358. Sidney Kimmel Cancer Center
  359. Siemens Healthineers
  360. Sierra Ventures
  361. SimplicityBio
  362. SJF Ventures
  363. Social Capital
  364. SocialGenomics
  365. Sonraí Analytics
  366. SOPHiA GENETICS
  367. Spanish Lung Cancer
  368. St. Joseph’s/Candler
  369. St. Jude Children's Research Hospital
  370. Stanford Health Care
  371. Stone Checker
  372. Strand Life Sciences
  373. Stryker
  374. Studio Management
  375. Sun Life
  376. Sunquest Information Systems
  377. Susman Ventures
  378. Sutter Health
  379. Swisscom Ventures
  380. Syapse
  381. T. Rowe Price
  382. Tabula Rasa HealthCare
  383. Takeda
  384. Taliaz
  385. Teamsters
  386. TeamViewer
  387. Techstart Ventures
  388. Teladoc Health
  389. TELUS Ventures
  390. Tempus Labs
  391. Ten Coves Capital
  392. TeraRecon
  393. Terumo
  394. The Mark Foundation for Cancer Research
  395. Parker Institute
  396. Thermo Fisher Scientific
  397. Thomas Jefferson University
  398. TIGAR Health Technologies
  399. Tiger Global Management
  400. Tiny VC
  401. Tmunity Therapeutics
  402. Topcon Healthcare
  403. TPG Biotech
  404. Translational Sciences Institute
  405. Translational Software
  406. Trapelo Health
  407. Trialbee
  408. TriCore Reference Laboratories
  409. Triesta Sciences
  410. TwinStrand Biosciences
  411. Twist Bioscience 
  412. Tydo
  413. UK Research and Innovation
  414. uMETHOD
  415. UnitedHealthcare
  416. University Hospital of Augsburg
  417. University of California
  418. University of Chicago
  419. University of Missouri Health Care
  420. University of Pittsburgh Medical Center (UPMC)
  421. US Orthopedic Alliance
  422. Vanderbilt-Ingram Cancer Center
  423. Vanderbilt University Medical Center
  424. Varian
  425. Verily Life Sciences
  426. Vicinity
  427. Vidence
  428. VigiLanz 
  429. Viking Global Investors
  430. Visiopharm
  431. Welfare Fund of Philadelphia
  432. Wellcome Sanger Institute
  433. Wisconsin Investment Partners
  434. Genuity Science (formerly known as WuXi NextCODE)
  435. XIFIN
  436. Y Combinator
  437. YouScript
  438. Zero Childhood Cancer
  439. ZS Associates

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com